Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Future Oncology
Gail J RobozHagop Kantarjian

Abstract

Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, randomized, double-blind, placebo-controlled QUAZAR AML Maintenance trial (CC-486-AML-001) examines CC-486 maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles) for patients aged ≥55 years with AML in first complete remission. The primary end point is overall survival. Secondary end points include relapse-free survival, safety, health-related quality of life and healthcare resource utilization. This trial will investigate whether CC-486 maintenance can prolong remission and improve survival for older patients with AML.

References

Apr 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A CassilethM J O'Connell
Dec 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T BüchnerG Zeile
Aug 9, 2001·Annals of Medicine·R Rabin, F de Charro
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Apr 3, 2004·Cancer Treatment Reviews·Alberto RedaelliChris L Pashos
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Feb 8, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G PrueF Cramp
Oct 24, 2006·British Journal of Haematology·UNKNOWN British Committee for Standards in HaematologyG Jackson
Nov 25, 2006·Hematology·Nicola Gökbuget, Dieter Hoelzer
Jun 13, 2008·Leukemia·G Garcia-ManeroS Sharma
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
Sep 10, 2008·Critical Reviews in Oncology/hematology·Shabbir M H AlibhaiMark D Minden
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerWolfgang Hiddemann
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Maria R Baer
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cecile PautasSylvie Castaigne
Jan 12, 2010·Current Opinion in Hematology·Utz KrugThomas Büchner
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato Bassan, Dieter Hoelzer
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Jan 18, 2011·Hematology·Selina M Luger
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillermo Garcia-ManeroBarry Skikne
Jul 12, 2011·International Journal of Clinical Pharmacy·Virginie NerichMarie-Christine Woronoff-Lemsi
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Apr 12, 2012·Blood·Ana Flávia Tibúrcio RibeiroRuud Delwel
Sep 28, 2012·Current Opinion in Oncology·Gail J Roboz
Oct 17, 2012·Leukemia Research·Annemieke LeunisCarin A Uyl-de Groot
Jun 22, 2013·British Journal of Haematology·Anjali ShahPaul C Lambert

❮ Previous
Next ❯

Citations

Jul 16, 2016·American Journal of Hematology·Elihu Estey
Jul 12, 2016·Rejuvenation Research·Léa MoulinRomain Debret
Jan 19, 2017·Current Opinion in Hematology·Geetika Bhatt, William Blum
Apr 5, 2019·American Journal of Hematology·Bruno C MedeirosDaniel A Pollyea
Mar 10, 2020·Blood Advances·Darren PanJohn Mascarenhas
Jan 7, 2020·Oncotarget·Ewa M KosciuczukLeonidas C Platanias
Sep 2, 2020·Expert Review of Hematology·Juan Eduardo Megías-VericatPau Montesinos
Feb 6, 2019·Therapeutic Advances in Hematology·Jan Philipp BewersdorfAmer M Zeidan
Aug 21, 2019·American Journal of Hematology·Matteo MolicaTapan M Kadia
Mar 30, 2019·Blood·Andrew H Wei
May 17, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel D Von HoffJohanna C Bendell
Dec 19, 2020·Signal Transduction and Targeted Therapy·Jenna L CarterYubin Ge
Feb 20, 2020·Experimental Eye Research·Alison G GreeneDeborah M Wallace

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
biopsy
flow cytometry

Clinical Trials Mentioned

NCT01757535

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.